adrenomedullin and Bipolar-Disorder

adrenomedullin has been researched along with Bipolar-Disorder* in 2 studies

Other Studies

2 other study(ies) available for adrenomedullin and Bipolar-Disorder

ArticleYear
Cross-disorder genomewide analysis of schizophrenia, bipolar disorder, and depression.
    The American journal of psychiatry, 2010, Volume: 167, Issue:10

    Family and twin studies indicate substantial overlap of genetic influences on psychotic and mood disorders. Linkage and candidate gene studies have also suggested overlap across schizophrenia, bipolar disorder, and major depressive disorder. The purpose of this study was to apply genomewide association study (GWAS) analysis to address the specificity of genetic effects on these disorders.. The authors combined GWAS data from three large effectiveness studies of schizophrenia (CATIE, genotyped: N=741), bipolar disorder (STEP-BD, geno-typed: N=1,575), and major depressive disorder (STAR*D, genotyped: N=1,938) as well as from psychiatrically screened control subjects (NIMH-Genetics Repository: N=1,204). A two-stage analytic procedure involving an omnibus test of allele frequency differences among case and control groups was applied, followed by a model selection step to identify the best-fitting model of allelic effects across disorders.. The strongest result was seen for a single nucleotide polymorphism near the adrenomedullin (ADM) gene (rs6484218), with the best-fitting model indicating that the effect was specific to bipolar II disorder. Findings also revealed evidence suggesting that several genes may have effects that transcend clinical diagnostic boundaries, including variants in NPAS3 that showed pleiotropic effects across schizophrenia, bipolar disorder, and major depressive disorder.. This study provides the first genomewide significant evidence implicating variants near the ADM gene on chromosome 11p15 in psychopathology, with effects that appear to be specific to bipolar II disorder. Although genomewide significant evidence of cross-disorder effects was not detected, the results provide evidence that there are both pleiotropic and disorder-specific effects on major mental illness and illustrate an approach to dissecting the genetic basis of mood and psychotic disorders that can inform future large-scale cross-disorder GWAS analyses.

    Topics: Adrenomedullin; Adult; Basic Helix-Loop-Helix Transcription Factors; Bipolar Disorder; Carrier Proteins; Chromosome Mapping; Chromosomes, Human, Pair 11; Cytokines; Depressive Disorder, Major; Female; Gene Frequency; Genetic Linkage; Genetic Predisposition to Disease; Genome-Wide Association Study; Genotype; Humans; Male; Nerve Tissue Proteins; Phenotype; Polymorphism, Single Nucleotide; Randomized Controlled Trials as Topic; Schizophrenia; Transcription Factors

2010
Possible role of nitric oxide and adrenomedullin in bipolar affective disorder.
    Neuropsychobiology, 2002, Volume: 45, Issue:2

    Nitric oxide (NO) has been implicated to play a role in the pathogenesis of depressive disorders. Adrenomedullin (AM) induces vasorelaxation by activating adenylate cyclase and also by stimulating the release of NO. AM immune reactivity is present in the brain, consistent with a role as neurotransmitter. Therefore, it is suggested that these two molecules may play a role together in the brain. We aimed to examine AM and NO in bipolar affective disorder (BPAD). Forty-four patients with BPAD and 21 healthy control subjects were included in this study. DSM-IV diagnosis of bipolar affective disorder (type I, manic episodes) was independently established by two psychiatrists and the Turkish version of the Bech-Rafaelson Mania Scale was administered. Also, a semistructured form was used to ascertain several sociodemographic and clinical variables of the patients. AM and NO were studied in plasma. The mean value of plasma NO levels in the BPAD group of 46.58 +/- 13.97 micromol/l was significantly higher than that of controls (31.81 +/- 8.14 micromol/l) (z = -4.15, p = 0.000). Mean plasma AM levels were found to be increased in patients with BPAD (35.13 +/- 5.26 pmol/l) compared to controls (16.22 +/- 3.02 pmol/l) (z = -6.16, p = 0.000). AM levels of BPAD patients were approximately 2-fold higher than controls. AM levels were positively correlated with the duration of hospitalization for the current episode and negatively correlated with the total duration of illness. Both NO and AM may have a pathophysiological role in BPAD (type I, manic episodes) and the clinical symptomatology and prognosis of BPAD.

    Topics: Adrenomedullin; Adult; Biomarkers; Bipolar Disorder; Chromatography, High Pressure Liquid; Drosophila Proteins; Female; Humans; Insect Proteins; Male; Nitric Oxide; Peptides; RNA-Binding Proteins; Severity of Illness Index

2002